Equities

Roquefort Therapeutics PLC

ROQ:LSE

Roquefort Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)5.60
  • Today's Change0.75 / 15.46%
  • Shares traded6.49m
  • 1 Year change-20.00%
  • Beta0.0324
Data delayed at least 20 minutes, as of Oct 31 2024 16:28 BST.
More ▼

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Dec 31 20212021
OPERATIONS
Net income(1)
Depreciation/depletion--
Non-Cash items0.36
Cash taxes paid, supplemental--
Cash interest paid, supplemental--
Changes in working capital(1.99)
Total cash from operations(2.62)
INVESTING
Capital expenditures--
Other investing and cash flow items, total(1.11)
Total cash from investing(1.11)
FINANCING
Financing cash flow items(0.16)
Total cash dividends paid--
Issuance (retirement) of stock, net4.79
Issuance (retirement) of debt, net--
Total cash from financing4.63
NET CHANGE IN CASH
Foreign exchange effects0.00
Net change in cash0.90
Net cash-begin balance/reserved for future use0
Net cash-end balance/reserved for future use0.90
SUPPLEMENTAL INCOME
Depreciation, supplemental--
Cash interest paid, supplemental--
Cash taxes paid, supplemental--
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.